Prevalence and genetic diversity of rotavirus infection in children with acute gastroenteritis in a hospital setting, Nairobi Kenya in post vaccination era: a cross-sectional study

Mary-Theresa Agutu1,2,4, Julliette Ongus2, Janeth Kombich3, Rose Kamenwa4, James Nyangao5, John Kagira2, Adelaide Ayoyi Ogutu6, Austine Bitek7

1Institute of Tropical Medicine and Infectious Diseases, Kenya, 2Jomo Kenyatta University of Agriculture and Technology, Kenya, 3University of Kabianga, Kenya, 4Aga Khan University Hospital, Kenya, 5Kenya Medical Research Institute, Kenya, 6Animal Health and Industry Training Institute, Kenya, 7Zoonotic Disease Unit, Kenya

4Corresponding author: Mary-Theresa Agutu, Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

Key words: Rotavirus, prevalence and genotype, vaccines

Received: 17/07/2016 - Accepted: 19/12/2016 - Published: 24/01/2017

Abstract

Introduction: Rotavirus is the leading cause of severe diarrhoea among infants and young children. Each year more than 611 000 children die from rotavirus gastroenteritis, and two million are hospitalized, worldwide. In Kenya, the impact of recent rotavirus vaccinations on morbidities has not been estimated. The study aimed at determining the prevalence and identity of rotavirus strains isolated from rotavirus-associated diarrhoea in vaccinated children presenting with acute gastroenteritis. Methods: Two hundred and ninety eight specimen from children presented at Gertrude Childrens’ Hospital from January to June 2012 were tested by EIA (Enzyme-linked Immunosorbent Assay) for rotavirus antigens. Molecular characterization was conducted on rotavirus-positive specimens. Extracted viral RNA was separated by polyacrylamide gel electrophoresis (PAGE) and the specific rotavirus VP4 (P-types) and VP7 (G-types) determined. Results: The prevalence rate of rotavirus was 31.5% (94/298). Of the rotavirus dsRNA, 57 (60.1%) gave visible RNA profiles, 38 (40.4%) assigned long electropherotypes while 19 (20.2%) were short electropherotypes. The strains among the vaccinated were G3P[4], G12P[6], G3P[6], G9P[4], G mixed G9/3P[4] and G1/3P[4]. Specifically, the G genotypes were G9/3 (5.3%), G9 (4.3%), G3 (4.3%), G12 (2.1%) and mixed G1/3 (1.1%). The P genotypes detected were P[4] (5.3%) and P[6] (5.3%). Conclusion: The present study demonstrates diversity in circulating genotypes with emergence of genotypes G3, G9, G12 and mixed genotypes G9/3 and recommends that vaccines should be formulated with a broad range of strains to include G9 and G12.

The Pan African Medical Journal. 2017;26:38. doi:10.11604/pamj.2017.26.38.10312

This article is available online at: http://www.panafrican-med-journal.com/content/article/26/38/full/

© Mary-Theresa Agutu et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Diarrhea is a leading killer of children in Kenya, causing approximately 9 percent of deaths in children less than five years of age [1]. It is estimated that 27% of all under five diarrheal disease hospitalization in Kenya is caused by rotavirus infection [2]. Current global estimates of mortality attributed to rotavirus-associated disease is 611,000 in children less than 5 years old [3] and mortality figures for sub-Saharan Africa total 145,000 annually [4]. Studies in Nigeria [5], Tunisia [6] and Kenya [7] have demonstrated that close to 90% of all children are infected with rotavirus by 2 years of age. In Kenya, the peak age of contracting gastroenteritis in children is 6-24 months [8-10]. It is estimated that, in Kenya, 68 deaths, 132 hospitalizations, and 21,800 clinic visits per 100,000 children aged less than 5 years annually are attributable to rotavirus diarrhoea [11]. Rotavirus belongs to the family Reoviridae, non-enveloped with a tri-layered icosahedral protein capsid and a genome of 11 double stranded RNA segments [12]. Rotavirus is the most common etiological agent associated with severe gastroenteritis leading to dehydration and death in young infants’ worldwide [3]. Rotaviruses are classified into groups, subgroups, serotypes and on the basis of electrophoretic migration of gene segments. The group and subgroup specificity are present on the inner capsid VP6. Thus, currently only rotavirus groups A, B and C have been identified as human and animal pathogens, while groups D, E, F, and G have only been identified in animals and birds [13-15]. Majority of rotavirus diarrhoea infections are caused by group A rotaviruses [16]. Group B rotavirus infection are uncommon but have recently been associated with outbreaks in China and India [17]. Group C rotavirus has been isolated in Kenyan children [18]. The genes encoding the outer capsid VP7 and VP4 form the basis of classification of group A rotaviruses into G and P genotypes, respectively [19]. There are twenty P genotypes with P [4], P [6], and P [8] most frequently associated with human infections. Further, there are 14 G genotypes with G-types 1, 2, 3 and 4, accounting for 80% of human infections. G8 and G9 are emerging as common genotypes with G9 being the most common in Kenya [20]. There are currently two orally administered rotavirus vaccines; Rotarix® (GlaxoSmithKline, Rixensart, Belgium) and Rotateq® (Merck & Co., Whitehouse Station, NJ), which have been available in Kenyan hospitals since 2007. Rotateq® vaccine contains five human-bovine reassortant viruses [W179-9 (G1P [5]), SC-2 (G2P [5]), W178-8 (G3P [5]), BrB-9 (G4P [5]) and W179-4 (G6P [8])]. These viruses were generated by crossing the naturally attenuated bovine rotavirus strain WC3 with five unique human rotaviruses each contributing a G1, G2, G3, or G4 VP7 or P[8] VP4 gene to one of the vaccine viruses [21]. Rotarix® vaccine is a human G1P [8] virus RIX4414 which was derived by serial passage in cell culture of a virus recovered from the stool of an infected child [22]. Human rotavirus vaccine has been shown to reduce hospitalizations as a result of gastroenteritis from any cause by up to 42% [22]. The present study was aimed at estimating prevalence of rotavirus gastroenteritis and the genetic diversity of rotavirus among the vaccinated children at the Gertrude’s Children Hospital, Nairobi, Kenya.

**Methods**

**Study setting and population**

This study was conducted at the Gertrude’s Children’s Hospital (GCH) between January and July 2012. The GCH is a leading Pediatric Hospital in Kenya which offers a variety of healthcare services to infants, school-age children, and teenagers. The laboratory work was undertaken at the rotavirus laboratory in the Centre for Virus Research (CVR) of the Kenya Medical Research Institute (KEMRI), Nairobi, Kenya. The study population comprised children presenting with gastroenteritis and attending the Gertrude’s Children’s Hospital. All children aged less than 5 years presenting with gastroenteritis at the hospital’s outpatient department, or during their first 48 hours of hospitalization and whose parents/guardians consented to the study, were included in this study. Those children who had developed gastroenteritis 48 hours after admission, or those with bloody stool with gastroenteritis and those whose parents/guardians did not give consent, were excluded from the study.

**Ethical clearance**

Ethical clearance for this study was obtained from the Scientific and Ethical Review Committees of the Kenya Medical Research Institute (KEMRI). Authorization to conduct the study was obtained from the Gertrude’s Children Hospital (GCH).
Research instruments

A structured questionnaire was used to collect the patients’ clinical and demographic data, both from the hospital records and from the consenting parents/guardians.

Study design and sample size determination

This was a hospital based cross-sectional study. The required sample size was calculated using Fischer et al (1998) formula. The sample size was calculated based on a previous prevalence study of rotavirus gastroenteritis in an urban hospital in Nairobi, which had been established to be 28.4% [23]. To detect this with a precision of 5% and confidence level at 95%, at least 313 patients was required. Only 298 had adequate sample for analysis.

Specimen collection and processing

Stool specimen was collected in a sterile polypot from a patient presenting with symptoms of gastroenteritis. They were stored in a -20°C freezer then transported in cool boxes to the processing laboratory at the Kenya Medical Research Institute (KEMRI), Nairobi. All procedures for working with biosafety level 2 (BSL2) agents such as rotavirus were observed as indicated in the WHO biosafety manual. All biohazardous materials were disposed off in the KEMRI incinerator. One milliliter of 10% (w/v) fecal suspension was prepared in phosphate-buffered saline (PBS), vortexed and clarified by centrifugation. The clarified supernatant was tested for the presence of group A rotavirus antigen using the commercial rotavirus antigen-detection Enzyme Linked Immunosorbent Assay (ELISA) (ProSpectTM Rotavirus Microplate Assay, Oxoid Ltd, United Kingdom). The procedures for detection were undertaken according to the manufacturer’s instructions.

Molecular analysis of ELISA-positive samples

The ELISA-positive samples were analyzed by polyacrylamide gel electrophoresis (PAGE) to identify the presence of rotavirus double stranded RNA. The procedure was as stipulated in the WHO Manual of Rotavirus detection and characterization methods [24]. The rotavirus dsRNA was run on 10% polyacrylamide resolving gels using a large format gel electrophoresis system (Hoefer SE600) and 3% spacer gel was used to enhance resolution of the ds RNA segments. Thirty microlitres (30µl) of each sample was loaded onto gels and electrophoresis was conducted at 100 V for 16-20h at room temperature. The gels were stained using silver staining to group the rotavirus in electropherotypes as described in the Laboratory Manual developed by the African Rotavirus Workshop in South Africa, 2002 [25]. Reverse transcriptase/polymerase chain reaction (RT-PCR) amplification was performed on the rotavirus ds RNA as described by the South and West African Regional Rotavirus Laboratories. The extracted ds RNA was re-suspended in 20µl of sterile iodized water and stored for use in PCR reactions. Briefly, the dsRNA was denatured by boiling at 94º C for 5 min followed by chilling in ice. The ds RNA was then reverse transcribed by incubating with reverse transcriptase and deoxynucleotides for 30 min at 42º C. The resultant cDNA was amplified in magnesium-dependent PCR. Briefly, for the G typing, a full-length 1062 gene segment 9, encoding for the VP7 glycoprotein was reverse transcribed and amplified by using primers sBeg9 [nucleotide (nt) 1-21, 5’-GGCTTAAAGAGAGAATTTCC-3’] and End 9 (nt 1062-1036, 5’GGTCACATCATACATTTCTAATCTTAAG-3’) followed by genotyping with cocktail of primers specific to six human serotypes G1- G4, G8 and G9 (aBT1, aCT2, aET3, aDT4, aAT8 and AFT9) and the consensus primer RVG 9 as described by [26, 27] shown in Table 1. For VP4 genotyping a full length 876 gene segment 4, encoding for the VP4 was reverse transcribed and amplified by using outer primers Con3 and Con2 as previously described [28] shown in Table 2 followed by genotyping with cocktail of primers specific to the five human P genotype P[4], P[6], P[8], P[9], and P[10] (2T-1, 3T-1, 1T-1, 4T-1, 5T-1) and consensus primer as Gentsch describes. PCR fragments were analyzed on 2% TAE agarose gels at 80-90 volts with appropriate molecular weight marker to determine the genotype of rotavirus strain. PCR bands were compared with molecular weight markers.

Data management and analysis

Data coding and analysis was performed done using the SPSS Version 20.0 software. Pearson’s chi-square was used to determine associations. Level of significance was fixed at 0.05 (p=0.05).

Results

Three hundred and thirty one (331) participants who met all the inclusion criteria were recruited. Of these, 298 stool specimens were examined in the final analysis. Ninety four (94) (31.5%) specimens were positive for rotavirus (Table 3). Rotavirus infection was most
common in children below 2 years of age. Among those infected, males were 46 (48.9%) while the females were 48 (51.1%) and 57 (60.1%) were still breastfeeding. Over 60% of the rotavirus cases had z-scores above median showing that they were of good nutritional status with the majority (41.5%) recording a median score (Table 3). Among the rotavirus positive cases, 33 (35.1%) had been vaccinated using either of the rotavirus vaccines available. Of these, 26 (78.8%) experienced diarrhoea for less than 3 days and only 2 had diarrhoea for more than 5 days (Table 4). Only 12 among those who were vaccinated stayed long in the hospital (more than 4 days). All 29 who had some dehydration were treated with intravenous fluids. A total of 94 EIA rotavirus-positive stool samples were subjected to PAGE and visible dsRNA migration patterns were obtained in 57 (60.1%) samples. Long electropherotypes were 38 (0.4%) while 19 (20.2%) displayed short patterns. Reverse transcription was done on 83 samples which had adequate RNA extracted. Overall, the results indicated the most predominant rotavirus strains were G3P [4] (8.5%) followed by G12P [6] (4.3%), G9P [6] (2.1%) and G3P [6] (1.1%). Many strains detected as mixed strains included G9/3P [4] (4.3%), G9/3P [6] (1.1%) and G1/3P [4] (1.1%). Others which were only partially G or P were as follows: G9P [NT] (9.6%), G9/3P [NT] (6.4%), G3P [NT] (3.2%), G1P [NT] (3.2), GNTP [4] (2.1%), and GNTP [6] (2.1%) (Table 5).

Discussion

This study was undertaken to evaluate the diversity of rotavirus (RV) genotypes and prevalence of RV infection in vaccinated children. Rotavirus was detected in 31.5% of the children presenting with gastroenteritis attending GCH in Nairobi, Kenya. The results from this study reveal an overall prevalence of rotavirus infection within the estimated ranges from previous studies. A study conducted from 1991 to 1994 demonstrated a prevalence of 22.5% [23] while a review of rotavirus research in children with diarrhea conducted in Kenya between 1975 and 2005 revealed rotavirus prevalence ranging from 11% to 56.2% in children less than 5 years and 6% in neonates [29]. Another study conducted at the Kenyatta National Teaching Hospital in children revealed a prevalence 59% [30]. A study conducted by Kiulia et al, between 2009 and 2011 demonstrated a prevalence of 37.8% and yet another study carried out in selected hospitals from Kiambu County in Kenya demonstrated a prevalence rate of 36.6 % [31]. After the introduction of rotavirus vaccines in the Kenyan market around 2007 after which this study was conducted 39.4% of the RV infected children were between 13 to 24 months in age followed by those less than 12 months at 37.2%. Consistently, most studies indicate that children less than 2 years are most affected by RV infection. This onset of infection correlates well with the decline of maternally acquired antibodies that disappear around 5 months [32]. In the present study gender difference was not significant. This is in agreement with another study looking at risk factors in pediatric diarrhea [33]. Among the rotavirus positive children, fifty four (57.4%) who were not vaccinated had some dehydration as compared to twenty eight (30%) who were vaccinated. A similar percentage among vaccinated and unvaccinated children were treated by intravenous rehydration. In this study among vaccinated children, G9 genotype was most common genotype at 23.4%. This is in agreement with a recent studies in Kenya where prevalence of 13-15% have been reported [9, 34, 35]. G9 has been recognized as the most widespread of the emerging genotypes. It was first reported in the United States in the early 1980s [36]. Soon after its detection, it disappeared for more than a decade; then re-emerged in the mid-1990s and has been affecting patients to date. Currently, the genotype comprises 4.1% of global rotavirus infections, and accounts for as high as 70% of rotavirus infections as reported by some studies [37]. Genotype G3 was the second most common genotype demonstrated in this study among the vaccinated children at 4.2%. In Kenya, genotype G3 strains were predominant circulating genotypes in the years 1999 and 2000 [29] but further reports on occurrence of this genotype declined. Studies done elsewhere around the world have reported a high occurrence of G3 genotype. A study in Korea and Ghana found G3 to be the second predominant G genotype at 26.4% and 12.7%, respectively [38, 39]. In Tunisia, a study in 2011 found that, G3 was the second most predominant at 25% [40]. Apart from being the predominant single G genotype, the Tunisian study established that it was also found in mixed infection with G9 and G1 at 17.5%. A study in India earlier mentioned detected 3% and 1.9% of diarrheal cases caused by G3 [41, 42]. The genotype G12 was also demonstrated in this study in both the vaccinated and unvaccinated children in equal percentage (4.3%). A study by Kiulia in 2009 to 2011 in Eastern Kenya [34] showed that G12 was found in 3.1% of the samples. Notably, G12 genotypes have been consistently detected in various countries, including in South Africa. [43, 44]. Since its first identification in the Philippines in 1990 [45], it has been reported worldwide [41]. In Malawi, G12 was the predominant circulating strain [46, 47]. G12 was in association with P [6] genotype and was found in young African children with symptomatic rotavirus
infection. In the current study, all the four G12 were in found to be in association with P [6] forming G12P [6] combination. This finding concurs with other early studies that have reported the occurrence of this combination of G12P [6] and G12P [4], isolated for the first time in Bangladesh [48] Genotype G1 as single and combined with G3 was also detected in this study. Genotype G2 was not identified and has not been documented for over 8 years in Kenya as documented by Kiulia et al [34]. The current study did not document any case of G1 genotype among vaccinated children although numerous molecular epidemiological studies have indicated that G1 is the most common circulating G type around the world [37, 49, 50]. Interestingly none of the specimens processed demonstrated genotype P [8]. According to these results genotype G1 and P [8] seems to be controlled well given that both are included in both vaccines available.

Conclusion

In the current study, prevalence of rotavirus infection remains high in spite of vaccination. Notably, vaccine uptake is still very low. Severity of the rotavirus associated gastroenteritis is reduced with reduced hospital stay. The great diversity and re-emerging rotavirus strains observed in this study especially in vaccinated children raises concerns as to whether the vaccine strains G1P[8], G1,G2,G3 and G4 would evoke sufficient heterotypic protection against other strains not present in the vaccine. This emphasizes the need for long-term rotavirus surveillance in order to establish the effectiveness of vaccines. The findings of high prevalence of G9 and the emergence of G12 strains in Kenya may have implications in the assessment of the efficacy of new rotavirus vaccines. Therefore, we recommend that vaccines should be formulated with a broad range of strains for better protection to include G9 and G12. The limitation of this study was that some of the guardians or parents presenting the children to the hospital did not exactly know the vaccine that was used. Further surveillance on use of vaccines and diversity of strains against vaccine used need to be done.

What is known about this topic

- Rotavirus is the most common etiological agent associated with severe gastroenteritis leading to dehydration and death in young infants worldwide (Parashar et al., 2006);
- Close to 90% of all children are infected with rotavirus by 2 years in these settings (Nyagao et al., 2010);
- Safe and effective vaccines are needed, especially in poorer countries where most deaths from the disease occur (Parashar et al., 2009).

What this study adds

- Overall, 94 of the 298 had detectable rotavirus antigen, representing a prevalence rate of 31.5%.
- The study documents the genetic diversity of group A rotaviruses associated with severe acute gastroenteritis in children less than 5 years of age from a hospital where some of the children were already are vaccinated against rotavirus;
- Emerging strains of G12 and G9 were found among these children infected with Rotavirus.

Competing interests

The authors declare no competing interest.

Authors’ contributions

MTA conceived the study, drafted the proposal, carried out data collection, laboratory examination, data analysis, interpretation of the results and ultimately finalized write up of the manuscript. JRO, JK and RWK gave technical advice in proposal development, in-process consultation and review of the manuscript. JN gave technical advice on sample testing and analysis, data analysis and review of the manuscript. JK, AAO and AB assisted in review of this paper. All authors have read and agreed to the final version of this manuscript and have equally contributed to its content and to the management of the case.

Acknowledgments

I am most grateful to all the children and parents/guardians who participated in this study. The assistance from the hospital laboratory staff of the Gertrude Children’s Hospital and Kenya Medical Research Institute (KEMRI) Rotavirus Laboratory was tremendous. This research was carried out with ethical approval from SSC (SSC No. 2100) and ERC, KEMRI and was authorized by GCH. This study was funded by the National Council for Science and
Technology (Ref. no. NCST/RCD & I/WS/3rd CALL/011). The Scientific Steering and Ethical Review Committees of KEMRI provided ethical clearance. To all of these I am most thankful.

Tables

Table 1: Oligonucleotide primers for G serotyping as designed by Gouvea et al., 1990 and Gault et al., 1999

Table 2: Oligonucleotide primers for P genotype PCR typing as designed by Gentsch et al., 1992

Table 3: Characteristics, clinical symptoms and treatment of children <5 years of age hospitalized with rotavirus and non-rotavirus gastroenteritis

Table 4: Clinical symptoms and treatment of vaccinated and non-vaccinated children infected by rotavirus

Table 5: Distribution of rotavirus genotypes circulating January 2012 to June 2012 among rotavirus positive and vaccinated children

References

1. Liu L, Johnson HL, Cousens S et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. The Lancet. 2012; 279 (9832): 2151-2161. PubMed | Google Scholar

2. Khagayi S, Burton DC, Onkoba R et al. High burden of rotavirus gastroenteritis in young children in rural western Kenya, 2010-2011. The Pediatric Infectious Disease Journal. 2014; 33(1S): S34-S40. PubMed | Google Scholar

3. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006 Feb; 12(2): 304-6. PubMed | Google Scholar

4. Molbak K, Fischer T, Mikkelsen CS. The estimation of mortality due to rotavirus infections in sub-Saharan Africa. Vaccine. 2000 Oct 15; 19(4-5): 393-5. PubMed | Google Scholar

5. Aminu M, Page NA, Ahmad AA, Umoh JU, Dewar J, Steele AD. Diversity of rotavirus VP7 and VP4 genotypes in Northwestern Nigeria. J Infect Dis. 2010 Sep 1; 202 Suppl: S198-204. PubMed | Google Scholar

6. Trabelsi A, Peenze I, Pager C, Jedd M, Steele D. Distribution of rotavirus VP7 genotypes and VP4 genotypes circulating in Sousse, Tunisia, from 1995 to 1999; emergence of natural human reassortants. J Clin Microbiol. 2000 Sep; 38(9): 3415-9. PubMed | Google Scholar

7. Nyangao J, Page N, Esona M, Peenze I, Gatheru Z, Tukey P, Steele AD. Characterization of human rotavirus strains from children with diarrhea in Nairobi and Kisumu, Kenya, between 2000 and 2002. J Infect Dis. 2010 Sep 1; 202 Suppl: S187-92. PubMed | Google Scholar

8. Cunliffe NA, Kilgore PE, Bresee JS, Steele AD, Luo N, Hart CA et al. Epidemiology of rotavirus diarrhea in Africa: a review to assess the need for rotavirus immunization. WHO Bull OMS. 1998; 76(5): 525-37. PubMed | Google Scholar

9. Central Bureau of Statistics (Kenya). Ministry of Health (Kenya) and Macro International. Kenya Demographic and Health Survey 2003. Matern Child Health 2004; 9: 123-52. Google Scholar

10. Gatheru Z, Kobayashi N, Adachi N, Chiba S, Muli J, Ogaja P et al. Characterisation of human rotavirus strains causing gastroenteritis in Kenya. Epidemiol Infect. 1993; 110: 419-23. PubMed | Google Scholar

11. Tate JE, Rheingans RD, O’Reilly CE, Odonyo B, Burton DC, Tornheim JA et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis. 2009 Nov 1; 200 Suppl 1: S76-84. PubMed | Google Scholar

12. Kapikan AZ, Hishino Y, Chanock RM. Rotaviruses. In Knipe DM and Hudson MJ. Fields Virology 4th Edition. 2001; 1787-1833. Google Scholar

13. Estes MK, Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MAB. Roizman B and Straus SE (ed) Rotaviruses and their replication, Fields virology, 4th ed, vol 2. Lippincott Williams &Wilkins, Philadelphia, Pa. 2001; p 1747–1786. Google Scholar
14. Saif LJ, Jiang B. Non-group A rotaviruses of humans and animals. Curr Top Microbiol Immunol. 1994; 185: 339-71. PubMed | Google Scholar

15. Saif LJ, Bohl EH, Theil KW, Cross RF, House JA. Rotavirus-like, calicivirus-like, and 23-nm virus-like particles associated with diarrhea in young pigs. J Clin Microbiol. 1980 Jul; 12(1): 105-11. PubMed | Google Scholar

16. Kapikan AZ, Hishino Y, Chanock RM, Rotaviruses. In: Howley PM, editor. Fields Virology 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins. 2001; 1787-1833. Google Scholar

17. Shariff M, Deb M, Singh R. A study of diarrhoea among children in Eastern Nepal with special reference to rotavirus. Indian J Med Microbiol. 2003 Apr-Jun; 21(2): 87-90. PubMed | Google Scholar

18. Mwenda JM, Peenze I, Omollo E. Human group C Rotavirus identified in Kenya. East Afr Med J. 2003; 80(2): 73-76. PubMed | Google Scholar

19. Estes MK, Kapikan AZ, Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B. Rotaviruses. In: Fields virology. Philadelphia: Lippincott Williams & Wilkins. 5th ed: 2007; 1917–74. Google Scholar

20. Cunliffe NA, Dove W, Bunn JEG, Ramadam MB, Nyangao JWO, Riveron RL, Cuevas LE, Hart A. Expanding global distribution of rotavirus genotype G9: Detection in Libya, Kenya and Cuba. Emerg Infect Dis. 2001; 7(5): 890-892. PubMed | Google Scholar

21. Matthijnssens J, Joelsson DB, Warakomski DJ, Zhou T, Mathis PK, Van Maanen MH, Ranheim TS, Clarlet M. Molecular and biological characterization of the 5 human-bovine rotavirus (WC-3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq. Virology. 2010 Aug 1; 403(2): 111-27. PubMed | Google Scholar

22. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006; 354(1): 11-22. PubMed | Google Scholar

23. Nakata S, Gatheru Z, Ukae S, Adachi N, Kobayashi N, Honma S, Muli J, Ogaja P, Nyangao J, Kiplagat E, Tukei P, Chiba S. Epidemiological study of the G genotype distribution of group A rotaviruses in Kenya from 1991 to 1994. J Med Virol. 1999 Jul; 58(3): 296-303. PubMed | Google Scholar

24. World Health Organization (WHO). Manual of rotavirus detection and characterization methods. WHO/IVB/08. 2009; 17: p 1-146. Google Scholar

25. MRC/MEDUNSA Diarrhoel Pathogens Research Unit and WHO. African Rotavirus Workshop 2002 Laboratory Manual. 2002. Google Scholar

26. Gouvea V, Glass RI, Woods P, Taniguchi K, Clark HF, Forrester B, Fang Z. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol. 1990 Feb; 28(2): 276-282. PubMed | Google Scholar

27. Gault E, Chikhi-Brachet R, Delon S, Schnepf N, Albiges L, Grimprel E, Girardet JP, Garbarg-Chenon A. distribution of human rotavirus G types circulating in Paris, France, during the 1997-1998 epidemic: high prevalence of type G4. Journal of Clinical Microbiology. 1999; 37: 2373-2375. PubMed | Google Scholar

28. Gentsch JR, Glass RI, Woods P, Gouvea V, Gorziglia M, Flores J, Das BK, Bhan MK. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol. 1992 Jun; 30(6): 1365-73. PubMed | Google Scholar

29. Kiulia NM, Kamenwa R, Irimu G, Nyangao JO, Gatheru Z, Nyachieo A, Steele AD, Mwenda J. The epidemiology of human rotavirus associated with diarrhoea in Kenya children: a review. J Trop Pediatr. 2008 Dec; 54(6): 401-5. PubMed | Google Scholar

30. Gatinu BW, Prevalence of group A rotavirus and electrolyte profiles in children presenting with acute diarrhea at KNH. Dissertation for Master of Medicine in Paediatrics and Child Health. University of Nairobi. 2007. Google Scholar
31. Apondi EW, Omondi JV, Ichinose Y. Detection and molecular characterization of rotavirus strains isolated from children attending selected health facilities in Kiambu district, Kenya. Thesis report submitted to Kenyatta University for a master science biotechnology. 2012; P 48-60. Google Scholar

32. Odiit A, Mulindwa A, Nalumansi E, Mphahlele J, Seheri LM, Mwenda JM, Kisakye A. Rotavirus prevalence and genotypes among children younger than 5 years with acute diarrhea at Mulango National Referral Hospital, Kampala, Uganda. Pediatr Infect Dis J. 2014 Jan; 33 Suppl 1: S41-4. PubMed | Google Scholar

33. Pennal G, Umoh J. Prevalence of Group A rotavirus infection and some risk factors in Pediatric diarrhea in Zaria, North Central Nigeria. Afr J Microbiol Res. 2010; 4: 1532-1536. Google Scholar

34. Kiulia NM, Nyaga MM, Seheri ML, Wolfaardt M et al. Rotavirus G and P types circulating in the Eastern Region of Kenya; predominance of G9 and emergence of G12 Genotypes. The Pediatric Infectious Disease Journal. 2014; 33 Supplement 1: S85-S88. PubMed | Google Scholar

35. Kang G, Desai R, Arora R, Chitambar S, Naik TN et al. Diversity of circulating rotavirus strains in children hospitalized with diarrhea in India, 2005-2009. Vaccine. 2013; 31(27): 2879-2883. PubMed | Google Scholar

36. Clark HF, Hoshino Y, Bell LM, Groff J, Hess G, Bachaman P et al. Rotavirus isolate WI61 representing a presumptive new human serotype. J Clin Microbiol. 1987 Sep; 25(9): 1757-62. PubMed | Google Scholar

37. Santos N, Hoshino Y. Global distribution of rotavirus genotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005 Jan-Feb; 15(1): 29-56. PubMed | Google Scholar

38. Phan Le Van, Ji-Yeon Kim, Sung-Lim Cho, Sun-Woo Nam, Inseok Lim, Hee-Joong Lee, Kijeong Kim, Sang-In Chung, Wonkeun Song, Kyu Man Lee, Moon-Soo Rhee, Jung-Sook Lee, and Wonyong Kim. Detection of Unusual Rotavirus Genotypes GBP [8] and G12P [6] in South Korea. Journal of Medical Virology. 2008; 80: 175-182. Google Scholar

39. Enweronu-Laryea CC, Sagoe KW, Damanka S, Larkey B, George EA. Rotavirus genotypes associated with childhood severe acute diarrhoea in southern Ghana. Virol J. 2013 Sep 14; 10: 287. PubMed | Google Scholar

40. Hassine-Zaafrene M, Sdiri-Loulizi K, Ben Salem I, Kaplon J, Ayouni S, Ambert-Balay K, Nabil S, Pierre P, Mahjoub A. The molecular epidemiology of circulating rotaviruses: three-year surveillance in the region of Monastir, Tunisia. BMC Infectious Diseases. 2011; 11(1): 266. Google Scholar

41. Kang G, Kelkar SD, Chitambar SD, Ray P, Naik T. Epidemiological profile of rotaviral infection in India: Challenges for the 21st Century. J Infect Dis. 2005 Sep 1; 192 Suppl 1: S120-6. PubMed | Google Scholar

42. Chakravarti A, Chauhan M, Sharma A, Verma. Distribution of human rotavirus G and P genotypes in a hospital setting from Northern India. Southeast Asian J Trop Med Public Health. 2010; 41(5): 1145-1153. PubMed | Google Scholar

43. Page NA, de Beer MC, Seheri LM et al. The detection and molecular characterization of human G12 genotypes in South Africa. J Med Virol. 2009 Jan; 81(1): 106-13. PubMed | Google Scholar

44. Matthijnssens J, Heylen E, Zeller M et al. Phylodynamic analyses of rotavirus genotypes G9 and G12 underscore their potential for swift global spread. Mol Biol Evol. 2010 Oct; 27(10): 2431-6. PubMed | Google Scholar

45. Taniguchi K, Urasawa T, Kobayashi N, Gorziglia M, Urasawa S. Nucleotide sequence of VP4 and VP7 genes of human rotaviruses with subgroup I specificity and long RNA pattern: implication for new G genotype specificity. J Virol. 1990; 64: 5640-4. PubMed | Google Scholar

46. Steele AD, Neuzil KM, Cunliffe NA, Madhi SA, Bos P et al. Human rotavirus vaccine rotarix® provides protection against diverse circulating rotavirus strains in African infants: A randomized controlled trial. BMC Infectious Diseases. 2012; 12: 213. Google Scholar
47. Nigel AC, Bagrey MN, Winifred D, Osamu N, Toyoko N, Arantza PC, Hart A, Kazembe PN, Mwansambo CCV. Genotype G12 Rotaviruses, Lilongwe, Malawi. Emerg Infect Dis. 2009 Jan; 15(1): 87-90. PubMed | Google Scholar

48. Paul SK, Ahmed MU, Hossain MA, Mahmud MC, Bhuiyan MR et al. Molecular characterization of Group A human rotavirus among hospitalized children and adults in Bangladesh: finding of emerging G 12 strain. Mymensingh Med J. 2010; 19(1): 16-26. PubMed | Google Scholar

49. Lacroix L, Galette-Lacour A, Altwegg M, Egli K, Schmidt M, Gervaix A. Disease burden of rotavirus gastroenteritis in children up to 5 years of age in two Swiss cantons: Pediatrician and hospital-based surveillance. Eur J Pediatr. 2010; 169(3): 319-325. Google Scholar

50. Van Man N, Luan Le T, Trach DD et al. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance, 1998–2003. J Infect Dis. 2005 Sep 1; 192 Suppl 1: S127-32. PubMed | Google Scholar

**Table 1:** Oligonucleotide primers for G serotyping as designed by Gouvea et al., 1990 and Gault et al.; 199

| Primer | Sequence (5’-3’) | Position(nt) | Strain (genotype) |
|--------|-----------------|--------------|-------------------|
| SBeg   | GGCTTTAAAAGAGAGAATTTC | 1-21 | Group A |
| Beg9   | GGCTTTAAAAGAGAGAATTTCGTGG | 1-28 | Group A |
| End9   | GGTCACATCATCAATTCTAATCTAAG | 1062-1036 | Group A |
| EndA   | ATAGTATAAAAATACCTGCCACCA | 922-944 | Group A |
| aAT8   | GTCACACATTTGTAAAATTCG | 178-198 | 69M (G8) |
| aBT1   | CAAGTACTCAGACTGATGGAAG | 314-335 | Wa (G1) |
| aCT2   | CAATGGATTTACATATATTCGGC | 411-435 | DS-1 (G2) |
| aDT4   | CGTTTTCTGGAGGAATGTTGG | 480-498 | ST-3 (G4) |
| aET3   | CGTTTTGAAGATTTGCCACAG | 689-709 | P (G3) |
| aFT9   | CAGATGTTAAGCACAATCTCAG | 757-776 | 69M (G9) |
| RVG9   | GTCACACATTTGTAAAATTCG | 1062-1044 | Group A |

**Table 2:** Oligonucleotide primers for P genotype PCR typing as designed by Gentsch et al., 1992

| Primer | Sequence (5’-3’) | Position (nt) | Strain (genotype) |
|--------|-----------------|--------------|-------------------|
| T1-1   | ACTTGGATACGGTC | 339-356 | KU [P8] |
| 2T-1   | CTATTGTAGAGGTAGAGTCC | 474-494 | RV5 [P4] |
| 3T-1   | TGCTGATTGTTGATTCAA | 259-278 | 1076 [P6] |
| 4T-1   | TGAGACATGGATTTGGAC | 385-402 | K8 [P9] |
| 5T-1   | ATCATAGTGTTGAGTCCG | 575-594 | 69M [P10] |
| Con3   | TGCTTGGCCATTTTATAGACA | 11-32 | Group A |
| Con2   | ATTTCCGACCATTTTATAACC | 868-887 | Group A |
Table 3: Characteristics, clinical symptoms and treatment of children <5 years of age hospitalized with rotavirus and non-rotavirus gastroenteritis

| characteristics                  | Rotavirus-positive cases | Rotavirus-negative |
|----------------------------------|--------------------------|--------------------|
|                                  | n=94(%)                  | n=204(%)           |
| **Sex**                          |                          |                    |
| Male                             | 46(48.9)                 | 118(57.8)          |
| Female                           | 48(51.1)                 | 89(43.6)           |
| **Age in months**                |                          |                    |
| 0-12                             | 35 (37.2)                | 101(49.5)          |
| 13-24                            | 37(39.4)                 | 59(29)             |
| 25-36                            | 6(6.4)                   | 23(11.3)           |
| 37-48                            | 8(8.5)                   | 16(7.8)            |
| 49-60                            | 8(8.5)                   | 8(3.9)             |
| **Vaccination status**           |                          |                    |
| Rotarix®                         | 21(22.3)                 | 38(18.6)           |
| Rotateq®                         | 4 (4.3)                  | 21(10.3)           |
| Vaccine used                     | 8(8.5)                   | 30(14.7)           |
| unascertained                    |                          |                    |
| Not vaccinated                   | 61(64.9)                 | 115(56.4)          |
| Breast feeding                   | 57(60.1)                 | 119(58.3)          |
| **Z-scores**                     |                          |                    |
| Median                           | 39 (41.5)                | 83(40.7)           |
| -1 sd                            | 14(14.9)                 | 46(22.5)           |
| -2 sd                            | 9(9.6)                   | 14(6.9)            |
| -3 sd                            | 1(1.1)                   | 8(3.9)             |
| 1 sd                             | 16(17)                   | 33(16.2)           |
| 2 sd                             | 4(4.3)                   | 6(2.9)             |
| 3 sd                             | 5(5.3)                   | 5(2.5)             |
Table 4: Clinical symptoms and treatment of vaccinated and non-vaccinated children infected by rotavirus

| Clinical symptom/treatment | Vaccinated (n=33) | Not vaccinated (n=61) |
|----------------------------|------------------|----------------------|
| **Diarrhoea**              |                  |                      |
| Duration of diarrhoea      |                  |                      |
| Equal to or < 3 days       | 26               | 41                   |
| >3<5                      | 5                | 8                    |
| >5 days                   | 2                | 12                   |
| Frequency of diarrhoea     |                  |                      |
| < or equal to 3            | 25               | 43                   |
| 4< or equal to 7           | 8                | 18                   |
| **Vomiting**               |                  |                      |
| Duration of vomiting       |                  |                      |
| Equal to or < 3 days       | 25               | 49                   |
| >3<5                      | 7                | 9                    |
| >5 days                   | 1                | 3                    |
| Frequency                 |                  |                      |
| < or equal to 3            | 23               | 38                   |
| 4< or equal to 7           | 6                | 17                   |
| >7                        | 4                | 6                    |
| **Hospital stay**          |                  |                      |
| Short < 3 days             | 18               | 33                   |
| Long “equal to or > 4 days | 12               | 25                   |
| **Dehydration**            |                  |                      |
| No dehydration            | 4                | 3                    |
| Some dehydration          | 29               | 54                   |
| Severe dehydration        | 0                | 4                    |
| **Treatment**              |                  |                      |
| Oral rehydration           | 2                | 3                    |
| Intravenous rehydration    | 29               | 57                   |
Table 5: Distribution of rotavirus genotypes circulating January 2012 to June 2012 among rotavirus positive and vaccinated children

| Strains    | Rotavirus positive n=94 | Vaccinated n=132 | Rotarix n=64 | Rotateq n=27 |
|------------|-------------------------|------------------|-------------|-------------|
|            | No. (%)                 |                  |             |             |
| G1P[NT]    | 3 (3.2)                 | 0                | 0           | 0           |
| G3P[4]     | 8 (8.5)                 | 2                | 1           | 1           |
| G3P[6]     | 1 (1.1)                 | 1                | 1           | 0           |
| G3P[NT]    | 3 (3.2)                 | 1                | 1           | 0           |
| G9P[6]     | 2 (2.1)                 | 1                | 0           | 0           |
| G9P[NT]    | 9 (9.6)                 | 3                | 1           | 0           |
| G9/3P[4]   | 4 (4.3)                 | 2                | 0           | 0           |
| G9/3P[6]   | 1 (1.1)                 | 1                | 0           | 1           |
| G9/3P[NT]  | 6 (6.4)                 | 3                | 2           | 1           |
| G1/3P[4]   | 1 (1.1)                 | 1                | 1           | 0           |
| GNT[4]     | 2 (2.1)                 | 0                | 0           | 0           |
| GNT[6]     | 2 (2.1)                 | 1                | 0           | 0           |
| GNT[NT]    | 29 (30.9)               | 7                | 3           | 2           |
| G12P[6]    | 4 (4.3)                 | 2                | 2           | 0           |
| Not genotyped | 18 (19.1)        | 107              | 52          | 22          |